Inovio aims for INO-3107 regulatory submission by mid-2025 while addressing key manufacturing issues
Q4 2024 Management View CEO Jacqui Shea highlighted that Inovio remains committed to transforming into a commercial-stage company, with a primary focus on advancing INO-3107, a DNA medicine for ...